ADIL - Adial Pharmaceuticals Awarded New United States Patent

2024-02-28 10:56:33 ET

DENVER, Colo., Feb 28, 2024 ( 247marketnews.com )- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) said, this morning, that it was awarded a new patent, number 11,905,562, issued on February 20, 2024 by the United States Patent and Trademark Office, which covers the Company’s lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder (OUD).

Adial is trading at $1.98, up $1.1067 (+126.73%), on trading volume of 35,071,381 shares. Its 52-week range is $0.765 to $15.00

“We are proud to be awarded another important patent that broadens our Intellectual Property portfolio and covers meaningful aspects of our lead asset, AD04, including its unique ability to target the serotonin transporter gene,” commented Cary Claiborne, CEO of Adial Pharmaceuticals. “We believe AD04 has significant potential to treat OUD and other drug dependencies in addition to our initial indication of alcohol use disorder. We remain focused on advancing AD04 toward commercialization for the treatment of alcohol use disorder and look forward to advancing OUD and other indications in the future.”

The post Adial Pharmaceuticals Awarded New United States Patent first appeared on 24/7 MarketNews .

For further details see: